

Quarterly Progress Review Q2 2024



Next-Generation injectable yttrium-90 therapy for solid cancer tumors.

VIVOS
PRECISION BRACHYTHERAPY

"If we can reach the tumor, we can kill it."

Precision Radionuclide Therapy™ (PRnT)

Executive Summary of Q2 2024

- Vivos Inc. has begun operating IsoPet® Animal Therapy and RadioGel® Human Therapy as two independent divisions. These divisions will operate standalone, with the objective of generating their own independent profitability. We have set clear goals and performance measures for each division to ensure their success. Our websites now reflect this change, with www.VivosIncUSA.com, www.IsoPet.com, and www.RadioGel.com each providing tailored information to interested parties. We also secured the domains www.vivosinternational.com for future initiatives.
- In addition to continuously expanding our patent protection in 83 different countries, we now own trademark applications/registrations for the following: ISOPET®, RADIOGEL®, ALPHA-GEL™, BETA-GEL™, GAMMA-GEL™, and PRECISION RADIONUCLIDE THERAPY™, PRNT™.



VIVOS



CONFERENCES IN 2024

ACVIM (American College of Veterinary Internal Medicine) June 6-8, 2024 – Minneapolis, MN

PacVet (Pacific Veterinary Conference) – July 11-14, 2024 – San Francisco, CA

IRPA (International Radiation Protection Association) Darrell Fisher will be presenting “Direct Interstitial Injection: An Approach to Optimizing Therapeutic Ratios for Safe and Effective Delivery of High-dose Radionuclide Therapy in Treating Solid Tumors” – July 7-12, 2024 – Orlando, FL

VCS (Cancer Society) – October 17-19 in Orlando. FL

AAEP (Association of Equine Practitioners), – December 7 -11 – Orlando, FL

CONFERENCES IN 2025

VMX (the world’s premier veterinary expo) – Jan 25-29 – Orlando, FL

97th Annual WVS Conference (the largest and oldest veterinary conference in the USA) March 2-5 – Las Vegas, NV

ACVIM (American College of Veterinary Internal Medicine) – June 2-14 – Louisville, KY

VCS (Veterinary Cancer Society) – Sept 25-27 – Salt Lake City, UT

ISOPET® REVIEW

ANIMAL THERAPY DIVISION – ISOPET®

- Our team attended the ACVIM (American College of Veterinary Internal Medicine) in Minneapolis, MN and now are focusing on several potential new clinics.
- We now use five social media platforms: Facebook, Instagram, LinkedIn, TikTok, and X to provide the most up to date information and maintain contact with current and new investors and to increase awareness in the animal health community.
- LeeAnna Binder, our head of marketing, converted her van into an IsoPet® marketing tool and recently left for a four-month marketing road trip across the US to visit clinics and conferences.
- We have launched an initiative to charge clinics for the right to use our intellectual property and the support we provide to become IsoPet® Precision Radionuclide Therapy™ certified.



RADIOGEL® REVIEW

HUMAN THERAPY DIVISION – RADIOGEL®

- The IDE application to the FDA was submitted on schedule at the end of the second quarter.
 - The VX2 testing report was completed and then subjected to an independent data review as recommended by the FDA. It demonstrated that RadioGel® remained in place in the tumor after gelation and had a very high therapeutic ratio.
 - The IUVO genotoxicity report was completed and concluded that RadioGel® was not genotoxic.
 - The hydrogel shelf-life study reports and the radiation effect of hydrogel reports were completed to improve the quality of the response to the previous comments.



RADIOGEL® REVIEW

- We are preparing the submission to the Mayo Clinic Independent Review Board and will be able to submit it promptly subject to receipt of the IDE clearance from the FDA.
- We repeated the training certification of the Mayo Clinic therapist to demonstrate improved processes and procedures.
- Two other Mayo lung cancer doctors attended the training since they are interested, subject to FDA clearance, in eventually using RadioGel® to treat lung cancer.

